Nuvectis Pharma Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Selling, General & Admin	7.52	7.52	6.01	3.35	0.02
Research & Development	14.67	14.38	12.03	2.45	-
Operating Expenses	22.19	21.9	18.03	5.79	0.02
Operating Income	-22.19	-21.9	-18.03	-5.79	-0.02
Interest & Investment Income	0.81	0.64	0.15	0	-
EBT Excluding Unusual Items	-21.38	-21.26	-17.89	-5.79	-0.02
Other Unusual Items	-1	-1	-1.2	-7.1	-
Pretax Income	-22.38	-22.26	-19.09	-12.89	-0.02
Net Income	-22.38	-22.26	-19.09	-12.89	-0.02
Net Income to Common	-22.38	-22.26	-19.09	-12.89	-0.02
Shares Outstanding (Basic)	16	16	13	4	4
Shares Outstanding (Diluted)	16	16	13	4	4
Shares Change (YoY)	14.00%	22.90%	196.55%	9.44%	-
EPS (Basic)	-1.40	-1.43	-1.51	-3.02	-
EPS (Diluted)	-1.40	-1.43	-1.51	-3.02	-
Free Cash Flow	-15.54	-15.95	-13.56	-9.5	-
Free Cash Flow Per Share	-0.97	-1.03	-1.07	-2.23	-
EBIT	-22.19	-21.9	-18.03	-5.79	-0.02

Source: S&P Capital IQ. Standard template.